About CTIBIOTECH
Founded in 2009, CTIBIOTECH develops advanced human tissue models for biomedical research, preclinical testing and translational medicine. The company combines human primary tissues, stem cell technologies and 3D bioprinting to create physiologically relevant cell and tissue models. Its platforms enable researchers to study disease mechanisms, evaluate drug candidates and investigate treatment responses using human-derived systems. CTIBIOTECH supports applications across oncology, dermatology, regenerative medicine, vaccine development, medical devices and cosmetic safety assessment. The company also provides alternatives to animal testing through humanized in vitro and ex vivo models.
Its portfolio includes custom 3D tissue models, patient-derived organoids, human cells and tissue products, together with contract research and preclinical testing services. CTIBIOTECH has developed specialised platforms for skin research, including CTISKIN™, as well as advanced oncology screening systems based on cancer biopsies, organoids and 3D bio-printed tumour models. These technologies support drug screening, toxicity testing, bioassay development, biomaterials evaluation and personalised medicine research. The company also develops organoid-based models for emerging applications such as hearing disorder research and pharmacological screening.
Europa Biosite’s subsidiaries distribute for CTIBIOTECH in Belgium, Canada, Denmark, Estonia, Finland, Iceland, Latvia, Lithuania, Luxembourg, Netherlands, Norway, Sweden, Switzerland and the United States of America.